{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:40:04Z","timestamp":1777632004682,"version":"3.51.4"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2008,8,14]],"date-time":"2008-08-14T00:00:00Z","timestamp":1218672000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1007\/s11239-008-0253-7","type":"journal-article","created":{"date-parts":[[2008,8,13]],"date-time":"2008-08-13T13:13:08Z","timestamp":1218633188000},"page":"215-219","source":"Crossref","is-referenced-by-count":17,"title":["Antithrombotic prophylaxis in patients with von Willebrand disease undergoing major surgery: when is it necessary?"],"prefix":"10.1007","volume":"28","author":[{"given":"Massimo","family":"Franchini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Targher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Montagnana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Lippi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,8,14]]},"reference":[{"key":"253_CR1","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood.V69.2.454.454","volume":"69","author":"F Rodeghiero","year":"1987","unstructured":"Rodeghiero F, Castaman G, Dini E (1987) Epidemiological investigation of the prevalence of von Willebrand\u2019s disease. Blood 69:454\u2013459","journal-title":"Blood"},{"key":"253_CR2","first-page":"94","volume":"88","author":"G Castaman","year":"2003","unstructured":"Castaman G, Federici AB, Rodeghiero F, Mannucci PM (2003) von Willebrand\u2019s disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment. Haematologica 88:94\u2013108","journal-title":"Haematologica"},{"key":"253_CR3","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/10408360600966753","volume":"44","author":"M Franchini","year":"2007","unstructured":"Franchini M, Lippi G (2007) The role of von Willebrand factor in hemorrhagic and thrombotic disorders. Crit Rev Clin Lab Sci 44:115\u2013149. doi: 10.1080\/10408360600966753","journal-title":"Crit Rev Clin Lab Sci"},{"key":"253_CR4","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra040403","volume":"351","author":"PM Mannucci","year":"2004","unstructured":"Mannucci PM (2004) Treatment of von Willebrand\u2019s disease. N Engl J Med 351:683\u2013694. doi: 10.1056\/NEJMra040403","journal-title":"N Engl J Med"},{"key":"253_CR5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/j.seminhematol.2004.10.001","volume":"42","author":"F Rodeghiero","year":"2005","unstructured":"Rodeghiero F, Castaman G (2005) Treatment of von Willebrand disease. Semin Hematol 42:29\u201335. doi: 10.1053\/j.seminhematol.2004.10.001","journal-title":"Semin Hematol"},{"key":"253_CR6","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0140-6736(95)90166-3","volume":"345","author":"T Koster","year":"1995","unstructured":"Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR (1995) Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345:152\u2013155. doi: 10.1016\/S0140-6736(95)90166-3","journal-title":"Lancet"},{"key":"253_CR7","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1055\/s-0037-1613227","volume":"88","author":"M Makris","year":"2002","unstructured":"Makris M, Colvin B, Gupta V, Shields ML, Smith MP (2002) Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand\u2019s disease. Thromb Haemost 88:387\u2013388","journal-title":"Thromb Haemost"},{"key":"253_CR8","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1055\/s-0037-1613225","volume":"88","author":"PM Mannucci","year":"2002","unstructured":"Mannucci PM (2002) Venous thromboembolism in von Willebrand disease. Thromb Haemost 88:378\u2013379","journal-title":"Thromb Haemost"},{"key":"253_CR9","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1182\/blood.V99.2.450","volume":"99","author":"PM Mannucci","year":"2002","unstructured":"Mannucci PM, Chediak J, Hanna W, Byrnes J, Marlies L, Ewenstein BM, Alphanate Study Group (2002) Treatment of von Willebrand disease with a high-purity factor VIII\/von Willebrand factor concentrate: a prospective, multicenter study. Blood 99:450\u2013456. doi: 10.1182\/blood.V99.2.450","journal-title":"Blood"},{"key":"253_CR10","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/j.1538-7836.2007.02588.x","volume":"5","author":"S Lethagen","year":"2007","unstructured":"Lethagen S, Kyrle PA, Castaman G, Haertel S, Mannucci PM, The Haemate P Surgical Study Group (2007) von Willebrand factor\/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. J Thromb Haemost 5:1420\u20131430. doi: 10.1111\/j.1538-7836.2007.02588.x","journal-title":"J Thromb Haemost"},{"key":"253_CR11","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1056\/NEJM200008173430702","volume":"343","author":"PA Kyrle","year":"2000","unstructured":"Kyrle PA, Minar E, Hirschl M et al (2000) High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 343:457\u2013462. doi: 10.1056\/NEJM200008173430702","journal-title":"N Engl J Med"},{"key":"253_CR12","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1160\/TH05-01-0013","volume":"93","author":"PS Wells","year":"2005","unstructured":"Wells PS, Langlois NJ, Webster MA, Jaffey J, Anderson JA (2005) Elevated factor VIII is a risk factor for idiopathic venous thromboembolism in Canada\u2014is it necessary to define a new upper reference range for factor VIII? Thromb Haemost 93:842\u2013846","journal-title":"Thromb Haemost"},{"key":"253_CR13","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1182\/blood.V79.12.3130.bloodjournal79123130","volume":"79","author":"PM Mannucci","year":"1992","unstructured":"Mannucci PM, Tenconi PM, Castaman G, Rodeghiero F (1992) Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial. Blood 79:3130\u20133137","journal-title":"Blood"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-008-0253-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-008-0253-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-008-0253-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T13:25:57Z","timestamp":1588857957000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-008-0253-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,14]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["253"],"URL":"https:\/\/doi.org\/10.1007\/s11239-008-0253-7","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,14]]}}}